文献速递皮肤肿瘤

评估局限性黑色素瘤治疗后患者主导监测的潜力(MEL-SELF):一项先导随机临床试验

Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial.
PubMed 文献 · JAMA Dermatol · 2022-01-01

这项先导随机临床试验在澳大利亚3家诊所纳入100例局限性黑色素瘤治疗后患者,1:1随机分入患者主导监测组(49例)或医生主导监测组(51例)。患者主导监测与皮肤自查频率增加(OR 3.5;95%CI 0.9-14.0)和彻底性增加(OR 2.2;95%CI 0.8-5.7)相关,对心理结局未检出不良影响,临床访视增加(RR 1.5;95%CI 1.1-2.1)。患者主导监测组诊断新原发黑色素瘤和1例局部复发8例(16%),其中5例(10%)在常规预约访视前发现;对照组3例(6%),均未在预约访视前发现(风险差10%;95%CI 2%-19%)。作者认为患者主导监测似乎安全、可行且可接受。

要点

  • 患者主导监测组皮肤自查频率OR 3.5(95%CI 0.9-14.0),彻底性OR 2.2(95%CI 0.8-5.7),均未达统计学显著。
  • 患者主导监测组临床访视较医生主导组增加(RR 1.5;95%CI 1.1-2.1),皮肤病灶切除RR 1.1(95%CI 0.6-2.0),未达统计学显著。
  • 患者主导监测组诊断新原发黑色素瘤和1例局部复发8例(16%),其中5例(10%)在预约访视前发现;对照组3例(6%),均未在预约访视前发现(风险差10%;95%CI 2%-19%)。

核心结论

  • 这项先导随机临床试验发现,局限性黑色素瘤治疗后患者主导监测似乎安全、可行且可接受。
  • 该先导研究的经验促使对同一干预的大型试验流程进行改进。

研究设计与样本

  • 在澳大利亚悉尼2家专科诊所和纽卡斯尔1家全科医生管理的初级保健皮肤癌诊所开展的先导随机临床试验。
  • 纳入100例已治疗局限性黑色素瘤、拥有智能手机、有伴侣协助皮肤自查且定期参加预约随访的患者,1:1随机分入患者主导监测组(n=49)或医生主导监测组(n=51)。
  • 研究于2018年11月1日至2020年1月17日进行,分析于2020年9月1日至2020年11月15日进行。
  • 主要结局为符合条件且被联系的患者中被随机化的比例;次要结局包括患者报告结局和临床结局。

主要发现

  • 326例符合条件且被联系的患者中,100例(31%)被随机化;平均(SD)年龄58.7(12.0)岁,53例(53%)为男性。
  • 患者报告结局数据可及66例参与者,临床结局数据可及100例参与者。
  • 与医生主导监测相比,患者主导监测与皮肤自查频率增加(OR 3.5;95%CI 0.9-14.0)和彻底性增加(OR 2.2;95%CI 0.8-5.7)相关,对心理结局未检出不良影响(癌症复发恐惧分量表评分;均差-1.3;95%CI -3.1-0.5)。
  • 与医生主导监测相比,患者主导监测组临床访视增加(RR 1.5;95%CI 1.1-2.1),皮肤病灶切除RR 1.1(95%CI 0.6-2.0),后续黑色素瘤诊断风险差10%(95%CI -2%-23%)。
  • 患者主导监测组诊断新原发黑色素瘤和1例局部复发8例(16%),其中5例(10%)在常规预约访视前发现;医生主导监测组3例(6%),均未在常规预约访视前发现(风险差10%;95%CI 2%-19%)。

关键数值与推荐

  • 主要结局:326例符合条件且被联系的患者中100例(31%)被随机化。
  • 皮肤自查频率:患者主导监测组较医生主导监测组OR 3.5(95%CI 0.9-14.0)。
  • 皮肤自查彻底性:患者主导监测组较医生主导监测组OR 2.2(95%CI 0.8-5.7)。
  • 癌症复发恐惧分量表评分:患者主导监测组较医生主导监测组均差-1.3(95%CI -3.1-0.5)。
  • 临床访视:患者主导监测组较医生主导监测组RR 1.5(95%CI 1.1-2.1);皮肤病灶切除RR 1.1(95%CI 0.6-2.0);后续黑色素瘤诊断风险差10%(95%CI -2%-23%)。

临床怎么用

  • 作者认为,局限性黑色素瘤治疗后患者主导监测似乎安全、可行且可接受。
  • 作者指出,该先导研究的经验促使对同一干预的大型试验流程进行改进。
  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patient-led surveillance is a promising new model of follow-up care following excision of localized melanoma. OBJECTIVE: To determine whether patient-led surveillance in patients with prior localized primary cutaneous melanoma is as safe, feasible, and acceptable as clinician-led surveillance. DESIGN, SETTING, AND PARTICIPANTS: This was a pilot for a randomized clinical trial at 2 specialist-led clinics in metropolitan Sydney, Australia, and a primary care skin cancer clinic managed by general practitioners in metropolitan Newcastle, Australia. The participants were 100 patients who had been treated for localized melanoma, owned a smartphone, had a partner to assist with skin self-examination (SSE), and had been routinely attending scheduled follow-up visits. The study was conducted from November 1, 2018, to January 17, 2020, with analysis performed from September 1, 2020, to November 15, 2020. INTERVENTION: Participants were randomized (1:1) to 6 months of patient-led surveillance (the intervention comprised usual care plus reminders to perform SSE, patient-performed dermoscopy, teledermatologist assessment, and fast-tracked unscheduled clinic visits) or clinician-led surveillance (the control was usual care). MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of eligible and contacted patients who were randomized. Secondary outcomes included patient-reported outcomes (eg, SSE knowledge, attitudes, and practices, psychological outcomes, other health care use) and clinical outcomes (eg, clinic visits, skin surgeries, subsequent new primary or recurrent melanoma). RESULTS: Of 326 patients who were eligible and contacted, 100 (31%) patients (mean [SD] age, 58.7 [12.0] years; 53 [53%] men) were randomized to patient-led (n = 49) or clinician-led (n = 51) surveillance. Data were available on patient-reported outcomes for 66 participants and on clinical outcomes for 100 participants. Compared with clinician-led surveillance, patient-led surveillance was associated with increased SSE frequency (odds ratio [OR], 3.5; 95% CI, 0.9 to 14.0) and thoroughness (OR, 2.2; 95% CI, 0.8 to 5.7), had no detectable adverse effect on psychological outcomes (fear of cancer recurrence subscale score; mean difference, -1.3; 95% CI, -3.1 to 0.5), and increased clinic visits (risk ratio [RR], 1.5; 95% CI, 1.1 to 2.1), skin lesion excisions (RR, 1.1; 95% CI, 0.6 to 2.0), and subsequent melanoma diagnoses and subsequent melanoma diagnoses (risk difference, 10%; 95% CI, -2% to 23%). New primary melanomas and 1 local recurrence were diagnosed in 8 (16%) of the participants in the intervention group, including 5 (10%) ahead of routinely scheduled visits; and in 3 (6%) of the participants in the control group, with none (0%) ahead of routinely scheduled visits (risk difference, 10%; 95% CI, 2% to 19%). CONCLUSIONS AND RELEVANCE: This pilot of a randomized clinical trial found that patient-led surveillance after treatment of localized melanoma appears to be safe, feasible, and acceptable. Experiences from this pilot study have prompted improvements to the trial processes for the larger trial of the same intervention. TRIAL REGISTRATION: http://anzctr.org.au Identifier: ACTRN12616001716459.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Ackermann DM, Dieng M, Medcalf E, et al. Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial. JAMA Dermatol. 2022. PMID: 34817543. doi:10.1001/jamadermatol.2021.4704

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。